Roy et al., 2024 - Google Patents
Julia Meidenbauer1, 2, 3, Matthias Wachter1, 2, 3, Sebastian R. Schulz4, Nada Mostafa1, 2, 3, Lilli Zülch1, 2, 3Roy et al., 2024
- Document ID
- 8472839774714890626
- Author
- Roy S
- Orth M
- Murugesan M
- Publication year
External Links
- 238000001959 radiotherapy 0 abstract description 249
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yang et al. | Tumor microenvironment in ovarian cancer: function and therapeutic strategy | |
| Lo et al. | The role of EBV-encoded LMP1 in the NPC tumor microenvironment: from function to therapy | |
| Cantini et al. | Emerging treatments for malignant pleural mesothelioma: where are we heading? | |
| Toniolo et al. | Inhibiting STAT5 by the BET bromodomain inhibitor JQ1 disrupts human dendritic cell maturation | |
| Li et al. | Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review | |
| US20240009223A1 (en) | 6-thio-2'-deoxyguanosine (6-thio-dg) results in telomerase dependent telomere dysfunction and cell death in various models of therapy-resistant cancer cells | |
| CN111148518A (en) | Methods of modulating regulatory T cells and immune responses using CDK4/6 inhibitors | |
| Luo et al. | Necroptosis-dependent immunogenicity of cisplatin: implications for enhancing the radiation-induced abscopal effect | |
| Huang et al. | Engineered sTRAIL-armed MSCs overcome STING deficiency to enhance the therapeutic efficacy of radiotherapy for immune checkpoint blockade | |
| Fang et al. | Cancer-associated fibroblast-like fibroblasts in vocal fold leukoplakia suppress CD8+ T cell functions by inducing IL-6 autocrine loop and interacting with Th17 cells | |
| Wei et al. | p53 function is compromised by inhibitor 2 of phosphatase 2A in sonic hedgehog medulloblastoma | |
| Chaudhary et al. | Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma | |
| Qin et al. | Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: Challenges and opportunities | |
| Bergerud et al. | Radiation therapy and myeloid-derived suppressor cells: breaking down their cancerous partnership | |
| Pandruvada et al. | Head and neck cancer treatment in the era of molecular medicine | |
| Haybaeck | Mechanisms of Molecular Carcinogenesis-Volume 2 | |
| Roy et al. | Julia Meidenbauer1, 2, 3, Matthias Wachter1, 2, 3, Sebastian R. Schulz4, Nada Mostafa1, 2, 3, Lilli Zülch1, 2, 3 | |
| Aftabi et al. | Therapeutic targeting of TGF‐β in lung cancer | |
| Meidenbauer et al. | Inhibition of ATM or ATR in combination with hypo-fractionated radiotherapy leads to a different immunophenotype on transcript and protein level in HNSCC | |
| KR102696859B1 (en) | Composition for enhancing cancer treatment effect containing C19 and use thereof | |
| US20220125770A1 (en) | Combination therapy of alk-positive neoplasia | |
| Liang et al. | Targeting CENP-E augments immunotherapy in non-small cell lung cancer via stabilizing PD-L1 | |
| Pendse et al. | A comprehensive analysis of cell‐autonomous and non‐cell‐autonomous regulation of myeloid leukemic cells: The prospect of developing novel niche‐targeting therapies | |
| Principe | Transforming Growth Factor β Signaling in the Pancreatic Tumor Microenvironment | |
| Frusteri | Targeting immune dysregulation mediated by FLIP and putative FLIP-related pathways to develop new therapeutic approaches |